Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR2 | Q969V1 | 9/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2758063 | 1.00 | MCHR2 (0.48) | MCHR2DRD2KCNH2SLC6A4CACNA1I | |
| SCHEMBL241429 | 1.00 | MCHR2 (0.48) | MCHR2DRD2KCNH2SLC6A4CACNA1I | |
| SCHEMBL2758244 | 0.92 | MCHR2 (0.57) | MCHR2DRD2KCNH2SLC6A4CACNA1I | |
| SCHEMBL2758153 | 0.90 | MCHR2 (0.41) | MCHR2DRD2KCNH2SLC6A4CACNA1I | |
| SCHEMBL2758066 | 0.90 | MCHR2 (0.41) | MCHR2DRD2KCNH2SLC6A4CACNA1I | |
| SCHEMBL2758202 | 0.89 | HTR1A (0.41) | MCHR2DRD2KCNH2SLC6A4HTR1A | |
| SCHEMBL2758018 | 0.89 | HTR1A (0.41) | MCHR2DRD2KCNH2SLC6A4HTR1A | |
| SCHEMBL2758156 | 0.89 | MCHR2 (0.39) | MCHR2DRD2KCNH2SLC6A4CACNA1I | |
| SCHEMBL2758003 | 0.89 | MCHR2 (0.39) | MCHR2DRD2KCNH2SLC6A4CACNA1I | |
| SCHEMBL2758008 | 0.89 | MCHR2 (0.40) | MCHR2DRD2KCNH2SLC6A4OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304423-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304423-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304423-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-8003660-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003660-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003660-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| WO-2007100664-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213315-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | MCHR2 159/4885DRD2 757/4885KCNH2 571/4885 |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | MCHR2 159/4885DRD2 757/4885KCNH2 571/4885 |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | MCHR2 159/4885DRD2 757/4885KCNH2 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.